|
A Study of Motexafin Gadolinium and Temozolomide for the Treatment of Malignant Gliomas Clinical Trials Information presented on Clinical Trials Search is not intended to be a substitute for qualified health advice, trips or treatment by using a genuine doctor. We aren't doctors. Always consult your mD on A Study of Motexafin Gadolinium and Temozolomide for the Treatment of Malignant Gliomas conditions. Clinical Trials Search.org is a site committed to listing clinical research studies in human subjects. A Study of Motexafin Gadolinium and Temozolomide for the Treatment of Malignant Gliomas Clinical research trials and A Study of Motexafin Gadolinium and Temozolomide for the Treatment of Malignant Gliomas health trials take place in a lot of of cities across the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the potency of new drugs. The aim of the studies / projects is to answer specific human medical questions. Clinical trials are a popular manner for physicians, government agencies, and private sector corporations to discover remedies for all kinds of circumstances, like A Study of Motexafin Gadolinium and Temozolomide for the Treatment of Malignant Gliomas. A Study of Motexafin Gadolinium and Temozolomide for the Treatment of Malignant Gliomas Clinical Trials and other clinical trials allow for volunteers to have health treatment alternatives before they are available to the general public. Many times the test subjects obtain treatment for without cost, and occasionally they are paid for their time. Sometimes there is a cost for a A Study of Motexafin Gadolinium and Temozolomide for the Treatment of Malignant Gliomas clinical trial. Subjects oftentimes recieve the most effective healthcare possible for their A Study of Motexafin Gadolinium and Temozolomide for the Treatment of Malignant Gliomas condition. Hazards are a reality, however, and could include additional or frequent doctor visits, healthcare dangers (perhaps life-threatening), and/or the treatment being ineffective. Trials are federally governed with exacting guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > A Study of Motexafin Gadolinium and Temozolomide for the Treatment of Malignant Gliomas  A Study of Motexafin Gadolinium and Temozolomide for the Treatment of Malignant Gliomas
A Study of Motexafin Gadolinium and Temozolomide for the Treatment of Malignant Gliomas
For Condition: Brain Neoplasm,Astrocytoma,Glioma,Oligodendroglioma,Glioblastoma
Status: Recruiting
Sponsor(s): Pharmacyclics ,
Synopsis: The purpose of this study is to find out about the safety of adding the investigational drug motexafin gadolinium to a standard course of chemotherapy with temolzolomide for patients with malignant glioma. Secondly, the study will determine how many patients will respond to this treatment.
Details:
Eligibility:
Study Type: Interventional, Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: - At least 18 years old - Histologically confirmed diagnosis of malignant gliomas that requires systemic antineoplastic treatment. Malignant glioma is defined as any of the following: Glioblastoma multiforme (GBM); Anaplastic astrocytoma (AA); Anaplastic oligodendroglioma; Anaplastic mixed glioma; Glioma not otherwise specified (except low-grade glioma) - ECOG performance status score of 0, 1, or 2 - Each patient must sign a study-specific informed consent form Exclusion Criteria: Laboratory values of: - Absolute neutrophil count < 2000/µL - Platelet count < 100,000/µL - AST or ALT > 2 x the upper limit of normal (ULN) - Alkaline phosphatase > 5 x ULN - Bilirubin > 2 x ULN - Creatinine > 2.0 mg/µL and - Plan to use any additional cancer therapy (e.g., systemic, radiation, surgery) during the study period - Women who are pregnant or lactating
Total Enrollment: 24
Location and Contact Information:
Barrow Neurological Institute *Recruiting*
Phoenix, Arizona, 85013
United States
Recruiting William Shapiro 602-456-7890
Additional Information:
Study ID Numbers: PCYC-0218;
Study Start Date:
Record last reviewed: March 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00080054
Other Glioblastoma Studies:
1. Safety and effectiveness study of G207, a tumor-killing virus, in patients with recurrent brain cancer
2. A Study of Motexafin Gadolinium and Temozolomide for the Treatment of Malignant Gliomas
3. Natural History of Patients with Brain and Spinal Cord Tumors
4. Procarbazine in Treating Patients With Recurrent Brain Tumor
5. STI571 to Treat Malignant Brain Tumors
Related Studies:
Other Glioblastoma Clinical Trials
Other Arizona Clinical Trials
Other Phoenix Clinical Trials
A Study of Motexafin Gadolinium and Temozolomide for the Treatment of Malignant Gliomas
|
|
|
|
|
|
|
|
